198 related articles for article (PubMed ID: 18452070)
1. Current therapy of myeloma induced renal failure.
Gertz MA
Leuk Lymphoma; 2008 May; 49(5):833-4. PubMed ID: 18452070
[No Abstract] [Full Text] [Related]
2. Lenalidomide efficacy in bortezomib-resistant myeloma.
Gozzetti A; Crupi R; Defina M; Bocchia M
Nat Rev Clin Oncol; 2010 Sep; 7(9):. PubMed ID: 20824907
[No Abstract] [Full Text] [Related]
3. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment.
Chanan-Khan AA; San Miguel JF; Jagannath S; Ludwig H; Dimopoulos MA
Clin Cancer Res; 2012 Apr; 18(8):2145-63. PubMed ID: 22328563
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide for bortezomib-resistant multiple myeloma.
Briani C; Berno T; Campagnolo M; Zambello R
Nat Rev Clin Oncol; 2010 Sep; 7(9):. PubMed ID: 20824906
[No Abstract] [Full Text] [Related]
5. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
Dimopoulos MA; Roussou M; Gavriatopoulou M; Zagouri F; Migkou M; Matsouka C; Barbarousi D; Christoulas D; Primenou E; Grapsa I; Terpos E; Kastritis E
Clin Lymphoma Myeloma; 2009 Aug; 9(4):302-6. PubMed ID: 19717380
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
[TBL] [Abstract][Full Text] [Related]
7. [Supportive care in multiple myeloma for continuing anti-myeloma therapies].
Shibayama H
Rinsho Ketsueki; 2014 Oct; 55(10):1999-2004. PubMed ID: 25297765
[No Abstract] [Full Text] [Related]
8. Novel agents in the frontline management of multiple myeloma.
Loong HH
Hematol Oncol Stem Cell Ther; 2008; 1(4):201-9. PubMed ID: 20058474
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib and lenalidomide effective in myeloma.
Cancer Biol Ther; 2007 Jan; 6(1):5. PubMed ID: 17612004
[No Abstract] [Full Text] [Related]
10. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
[TBL] [Abstract][Full Text] [Related]
11. [It is not necessary to use novel agents to all patients with newly diagnosed myeloma as an initial therapy].
Takamatsu Y
Rinsho Ketsueki; 2012 Jun; 53(6):587-93. PubMed ID: 22790633
[No Abstract] [Full Text] [Related]
12. Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens.
Roussou M; Kastritis E; Migkou M; Psimenou E; Grapsa I; Matsouka C; Barmparousi D; Terpos E; Dimopoulos MA
Leuk Lymphoma; 2008 May; 49(5):890-5. PubMed ID: 18464107
[TBL] [Abstract][Full Text] [Related]
13. [Clinical study of bortezomib in the treatment of multiple myeloma patients with renal failure].
Cao ZG; Liu M; Zhou HW
Zhonghua Xue Ye Xue Za Zhi; 2013 Jan; 34(1):74-5. PubMed ID: 23597473
[No Abstract] [Full Text] [Related]
14. Novel agents for multiple myeloma treatment.
Ribatti D; Vacca A
Curr Pharm Biotechnol; 2006 Dec; 7(6):395. PubMed ID: 17168654
[No Abstract] [Full Text] [Related]
15. Multiple myeloma.
Kyle RA; Rajkumar SV
N Engl J Med; 2004 Oct; 351(18):1860-73. PubMed ID: 15509819
[No Abstract] [Full Text] [Related]
16. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
Dimopoulos MA; Roussou M; Gkotzamanidou M; Nikitas N; Psimenou E; Mparmparoussi D; Matsouka C; Spyropoulou-Vlachou M; Terpos E; Kastritis E
Leukemia; 2013 Feb; 27(2):423-9. PubMed ID: 22763386
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
[TBL] [Abstract][Full Text] [Related]
18. New treatments in multiple myeloma: beyond optimal treatment.
Harousseau JL
Ann Oncol; 2008 Jul; 19 Suppl 5():v68-70. PubMed ID: 18611904
[No Abstract] [Full Text] [Related]
19. [Molecular-targeted therapy of multiple myeloma].
Iida S
Nihon Naika Gakkai Zasshi; 2010 Jan; 99(1):132-9. PubMed ID: 20376958
[No Abstract] [Full Text] [Related]
20. [Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure].
Muta T; Nakanishi H; Yasunaga M; Senba S; Murakami H; Kan S; Ueda Y; Fujisaki T
Gan To Kagaku Ryoho; 2011 Feb; 38(2):237-41. PubMed ID: 21368487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
